Ann: Invion announces Rights Issue Entitlement Of, page-30

re: Ann: Invion announces Rights Issue Entitl... I research extensively and everywhere I go I see quality decisions being made, like Numoda. Numoda was signed by invion before trials. Its perhaps the know how cbio lacked.

These little collaborations with quality partners, Altoona, Numoda, and 3M de-risk the trials to some extent. They are, I suspect, Garner and Glass contacts, based in Philedephia. For instance the 1991 founder of Altoona (Dr K) is heading the inv103 study. Little touches like that assure me that the network built over a long career in clinical trials is working in shareholders favour.

another little touch in picking up Zafirlukast as a parallel dev with Nadolol, nice efficiency there. Again Glass I suspect. Its like two for the price of one. These are good strategic decisions which require forethought. They also require contacts and experience.